NCT07379645

A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes

PepZinGI® Crossover Heartburn Clinical Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: NutriScience Innovations, LLC · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Accepted

Summary

This decentralized, randomized, double-blind, placebo-controlled, two-period crossover study will evaluate whether PepZinGI® (zinc-L-carnosine) reduces food-triggered heartburn compared with placebo. Participants (N=50) complete two 1-week treatment periods (PepZinGI® and placebo) separated by a 2-week washout, for a total of 29 days. Primary outcomes are heartburn severity and frequency measured by the NutriScience Heartburn Questionnaire; secondary outcomes include PROMIS GI Reflux-13a, time to relief, rescue medication use, wearable-derived sleep metrics, Karolinska Sleep Scale, sleep diary entries, and satisfaction. All activities are remote through Alethios; no in-person visits.

Conditions

• Heartburn

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	PepZinGI	75 mg patented zinc-L-carnosine complex
DIETARY_SUPPLEMENT	Placebo	\<0.1 mg zinc-L-carnosine

Timeline

• Start date: 2026-01-15
• Primary completion: 2026-05-01
• Completion: 2026-07-01
• First posted: 2026-01-30
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States